Read our analysis on how changes to the Section 505 of the Federal Food, Drug, and Cosmetic Act introduced by the FDA Modernization Act 2.0 can influence development of exosome-based therapies.
INSIGHTS04 (pdf, new tab)
Similar Posts
Introducing KnowlEx™ Cloud
Are you ready to take a peek behind the curtain of Exosome Consulting and see how we help our clients make the right…
Exosome-based diagnostics and therapeutics markets
Our new INSIGHTS paper, “Investing into extracellular vesicle-based diagnostic and therapeutics. Uncovering the opportunities, challenges, and restraints in the emerging markets.” is live….
ESG and exosome-focused companies
The end of the era of cheap money, characterized by low-interest rates and easy access to credit, has significant implications for businesses seeking…
